Merhaba Misafir

Amiselimod: A new oral agent in the treatment of multiple sclerosis


The first approved oral agent for multiple sclerosis, which is a chronic, inflammatory, demyelinating, and autoimmune disease of the central nervous system, was fingolimod. Fingolimod decreases circulating lymphocyte numbers by preventing their departure from lymphoid tissues due to its sphingosine-1-phosphate (S1P) receptor blocking effect. Fingolimod may cause temporary bradycardia within 6 hours of the first dose. This effect is due to “G protein coupled inwardly rectifying potassium channel” (GIRK) activation via S1P1 and S1P3 receptors in atrial myocytes. Amiselimod binds to S1P1 receptors with a higher affinity than S1P2-5 receptors and causes GIRK activation 5 times less compared with fingolimod.

Yayınlandığı Kaynak : Türk Nöroloji Dergisi
  • Yıl : 2017
  • DOI : 10.4274/tnd.90018
  • Cilt : 23
  • ISSN : 1301-062X
  • Sayı : 3
  • eISSN : 1309-2545
  • Sayfa Aralığı : 148-149
  • IO Kayıt No : 58190
  • Yayıncı : Türk Nöroloji Derneği